Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

David Joseph Kwiatkowski, M.D., Ph.D.

Co-Author

This page shows the publications co-authored by David Kwiatkowski and Amin Nassar.
Connection Strength

5.201
  1. Distribution of KRASG12C Somatic Mutations across Race, Sex, and Cancer Type. N Engl J Med. 2021 01 14; 384(2):185-187.
    View in: PubMed
    Score: 0.942
  2. A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma. Br J Cancer. 2020 02; 122(4):555-563.
    View in: PubMed
    Score: 0.875
  3. Mutations and Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. Mol Cancer Ther. 2020 02; 19(2):690-696.
    View in: PubMed
    Score: 0.865
  4. Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites. Clin Cancer Res. 2019 04 15; 25(8):2458-2470.
    View in: PubMed
    Score: 0.817
  5. CDKN2A Alterations and Response to Immunotherapy in Solid Tumors. Clin Cancer Res. 2021 Jul 15; 27(14):4025-4035.
    View in: PubMed
    Score: 0.242
  6. MITF is a driver oncogene and potential therapeutic target in kidney angiomyolipoma tumors through transcriptional regulation of CYR61. Oncogene. 2021 01; 40(1):112-126.
    View in: PubMed
    Score: 0.232
  7. Plasma cell-free DNA variant analysis compared with methylated DNA analysis in renal cell carcinoma. Genet Med. 2020 08; 22(8):1366-1373.
    View in: PubMed
    Score: 0.224
  8. Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinoma. Genet Med. 2020 04; 22(4):709-718.
    View in: PubMed
    Score: 0.219
  9. Tumors with TSC mutations are sensitive to CDK7 inhibition through NRF2 and glutathione depletion. J Exp Med. 2019 11 04; 216(11):2635-2652.
    View in: PubMed
    Score: 0.215
  10. Sequential Response to FGFR3 Inhibition With Subsequent Exceptional Response to Atezolizumab in a Patient With FGFR3-TACC3 Fusion-Positive Metastatic Urothelial Carcinoma. JCO Precis Oncol. 2018; 2.
    View in: PubMed
    Score: 0.198
  11. Enrichment of FGFR3-TACC3 Fusions in Patients With Bladder Cancer Who Are Young, Asian, or Have Never Smoked. JCO Precis Oncol. 2018; 2.
    View in: PubMed
    Score: 0.196
  12. RAF1 amplification drives a subset of bladder tumors and confers sensitivity to MAPK-directed therapeutics. J Clin Invest. 2021 Sep 23.
    View in: PubMed
    Score: 0.062
  13. Trans-ethnic variation in germline variants of patients with renal cell carcinoma. Cell Rep. 2021 03 30; 34(13):108926.
    View in: PubMed
    Score: 0.060
  14. Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors. Cancer Immunol Res. 2020 08; 8(8):1075-1084.
    View in: PubMed
    Score: 0.056
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.